baber/WOPTO huggingface dataset:
Patent NZ-580005-A (NZ)
Title: Probiotic bifidobacterium strain 41382
Inventor: MACSHARRY JOHN
IPC: A61K35/74
Filed: 2008-03-28
Abstract: Disclosed is an isolated strain of Bifidobacterium deposited at NCIMB with accessionnumber 41382. Further disclosed are formulations containing said Bifidobacterium strain and uses thereof.
Patent NZ-582466-A (NZ)
Title: Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin
Inventor: HUSSA ROBERT
IPC: C12Q1/68
Filed: 2005-07-29
Abstract: Disclosed is a method for detecting the presence of cervical cancer or cancerous or precancerous cervical cells in a subject comprising testing for an oncofetal fibronectin in a sample from the subject, wherein oncofetal fibroncctin is defined as a protein or protein fragment that specifically binds to a monoclonal antibody FDC-6 and wherein the presence of an oncofetal fibronectin positive sample indicates the presence of cervical cancer or cancerous or pre-cancerous cervical cells in the subject.
Patent NZ-582618-A (NZ)
Title: Drug selection for lung cancer therapy using antibody-based arrays
Inventor: SINGH SHARAT
IPC: C12Q1/00
Filed: 2008-07-11
Abstract: Disclosed is an in vitro method for selecting a suitable anticancer drug for the treatment of a lung tumor, the method comprising: (a) isolating cells of the lung tumor after administration of an anticancer drug, or prior to incubation with the anticancer drug; (b) lysing the isolated cells to produce a cellular extract; (c) detecting an activation state of a plurality of signal transduction molecules in the cellular extract using an assay comprising a plurality of dilution series of capture antibodies specific for the plurality of signal transduction molecules, wherein the capture antibodies are restrained on a solid support, and wherein the plurality of signal transduction molecules comprises Her3 (ErbB3); and (d) determining whether the anticancer drug is suitable or unsuitable for the treatment of the lung tumor by comparing the activation state detected for the plurality of signal transduction molecules with a reference activation profile generated in the absence of the anticancer drug.
Patent NZ-584935-A (NZ)
Title: Method of making mashable potatoes
Inventor: TIFFANY LINDA ELAINE
IPC: A23L19/12
Filed: 2008-10-24
Abstract: Disclosed is a method of making frozen, re-heatable, and mashable potato pieces comprising: cooking potato pieces such that said potato pieces retain structural integrity, wherein said potato pieces are cooked in hot water or by steaming; dewatering said potato pieces; freezing said potato pieces to form frozen, reheatable, and mashable potato pieces; and packaging said potato pieces in a reheatable container to form packaged frozen, reheatable, and mashable potato pieces. The potatoes can be peeled or unpeeled and are particularly Russet Burbank potatoes, Russet Norkota potatoes, Red-skinned potatoes , sweet potatoes and combinations of these. Also disclosed are mashable potato pieces prepared by this process.
Patent NZ-586320-A (NZ)
Title: Chair for transmitting processed sound to sitter as vibrations
Inventor: COHEN DANIEL
IPC: A47C13/00
Filed: 2008-12-06
Abstract: Disclosed is an apparatus for transmitting vibrations to a user. The apparatus is comprised of a seating configuration (70), an electromagnetic driver connected to the seating configuration (70), a signal processor and an amplifier (501). The signal processor is adapted to receive a first spectrum audio signal. The signal processor translates the first spectrum audio signal into a second spectrum audio signal, with frequency components of the first spectrum audio signal being translated into frequency components of the second spectrum audio signal. The amplifier (501) receives the second spectrum audio signal and provides an amplified output signal to the electromagnetic driver.
Patent NZ-587433-A (NZ)
Title: Compounds and method for reducing uric acid
Inventor: O'NEIL JAMES DENNEN
IPC: A61P25/28
Filed: 2009-03-13
Abstract: Disclosed is the use of a compound of Formula I or a pharmaceutically acceptable salt thereof in the treatment of a condition selected from the group consisting of gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyperuricemia, tumor-lysis syndrome and cognitive impairment, Wherein the compound is administered in an amount effective to reduce the uric acid concentration in blood of, or increase uric acid excretion from, the subject. Specific examples of compounds of formula I include: 2-(3-(2,6-Dimethylbenzyloxy)-4-methoxyphenyl)acetic acid; Methyl 3-(3-(2,6-dimethylbenzyloxy)phenyl)-3-oxopropanoate; 3-(3-(2,6-Dimethylbenzyloxy)phenyl)propanoic acid; and 2-(3-(3,5-Dimethylbenzyloxy)phenyl)acetic acid;
Patent NZ-589825-A (NZ)
Title: Heterocyclic compound and use thereof
Inventor: KUROITA TAKANOBU
IPC: A61K31/4184
Filed: 2009-06-17
Abstract: Disclosed herein are Benzimidazole carboxamide derivatives of formula (I), wherein the substituents are as defined within the specification, processes for their preparation, compositions comprising said compounds and uses thereof. Said compounds have useful renin inhibitory activity and as such is useful in the treatment of hypertension, various organ damages attributable to hypertension and circulatory disease. Specifically preferred examples include: · N-[(3S,5R)-5-carbamoylpiperidin-3-yl]-1-(4-methoxybutyl)-N-(2-methylpropyl)-1H-benzimidazole-2-carboxamide; · N-{ (3S,5R)-5-[1-hydroxyethyl]piperidin-3-yl} -1-(4-methoxybutyl)-N-(2-methylpropyl)-1H-benzimidazole-2-carboxamide; · 1-(4-Methoxybutyl)-N-(2-methylpropyl)-N-[(3S,5R)-5-(morpholin-4-ylcarbonyl)piperidin-3-yl]-1H-benzimidazole-2-carboxamide; · 1-(4-Hydroxybutyl)-N-(2-methylpropyl)-N-[(3S,5R)-5-(morpholin-4-ylcarbonyl)piperidin-3-yl]-1H-benzimidazole-2-carboxamide; · 1-(4-Methoxybutyl)-N-[(3S,5R)-5-(morpholin-4-ylcarbonyl)piperidin-3-yl]-N-propyl-1H-benzimidazole-2-carboxamide.
Patent NZ-590872-A (NZ)
Title: Process for the preparation of polypeptide glatiramer acetate
Inventor: HSIAO TSUNG-YU
IPC: C07K1/00
Filed: 2009-08-05
Abstract: A process of making a polypeptide or a pharmaceutically acceptable salt thereof is disclosed, wherein the polypeptide comprises L-alanine, L-tyrosine, L-glutamate, and L-lysine, and the process comprises reacting a L-lysine protected polypeptide, which comprises L-alanine, L-tyrosine, L-glutamate, and L-lysine that is protected with a first protecting group, with a tetraalkylammonium hydroxide in water to remove the first protecting group, and wherein the L-lysine protected polypeptide is prepared by a process comprising:(a) polymerizing a mixture of the N-carboxyanhydrides of L-alanine, L-tyrosine, L-glutamate that is protected with a second protecting group, and L-lysine that is protected with the first protecting group in a solvent to obtain a protected polypeptide; and(b) reacting the protected polypeptide in step (a) with hydrobromic acid in acetic acid to remove the second protecting group and to obtain the L-lysine protected polypeptide.
Patent NZ-591824-A (NZ)
Title: Butyrylcholinesterase ligands as diagnostic tools and treatment for deseases of the nervous system
Inventor: DARVESH SULTAN
IPC: A61K31/40
Filed: 2009-08-28
Abstract: 591824 Disclosed are butyrylcholinesterase compounds of Formula I. The compounds are useful for the early identification, treatment and diagnosis of Alzheimer's disease and related diseases of the nervous system, especially as regards their use as contrast agents and/or radioligands in Computer Aided Tomography, Single Photon Emission Computer Tomography, and/or Positron Emission Tomography.
Patent NZ-591891-A (NZ)
Title: Leavening composition comprising water, yeast and a dough conditioner in the form of an emulsifier
Inventor: POINTING GREGORY JAMES
IPC: A21D8/04
Filed: 2009-09-24
Abstract: Disclosed is a composition for leavening a dough or batter, the composition including water, yeast and a dough conditioner in the form of an emulsifier, the emulsifier being provided in an amount to increase the viscosity of the composition thereby minimising phase separation of yeast in the composition; and wherein the emulsifier is sodium stearoyl lactylate (SSL). Further disclosed is a composition for leavening a dough or batter, the composition including water, yeast and a dough conditioner in the form of an emulsifier, the emulsifier being provided in an amount to increase the viscosity of the composition thereby minimising phase separation of yeast in the composition: and wherein the composition does not include a gum or homopolysaccharide.
Patent NZ-595411-A (NZ)
Title: Bioavailable compositions of amorphous alpha-(n-sulfonamido)acetamide compound
Inventor: HARTLEY RUILING F
IPC: A61K9/14
Filed: 2010-04-12
Abstract: 595411 BIOAVAILABLE COMPOSITIONS OF AMORPHOUS ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND Amorphous solid dispersion compositions containing (2R)-2-[[(4-chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide and either polyvinylpyrrolidone-vinyl acetate or hydroxypropylmethylcellulose acetate succinate are provided for tabletting.
Patent NZ-597046-A (NZ)
Title: Use of alpha-toxin for treating and preventing staphylococcus infections
Inventor: TAYLOR KIMBERLEY L
IPC: A61K39/40
Filed: 2007-02-27
Abstract: Patent No. 597046 Disclosed is a composition comprising an S. aureus alpha-toxin antigen, a S. aureus Type 5 antigen, a S. aureus type 8 antigen, a microbial surface components recognising adhesive matrix molecules (MSCRAMM) protein and a pharmaceutically acceptable carrier, wherein said alpha-toxin antigen contains at least two alterations, relative to wild-type S. aureus alphatoxin, that reduce its toxicity wherein a first alteration is a chemical alteration and a second alterations is a molecular alteration selected from the group consisting of molecular alteration of amino acids Ala1-Val20, Lys110-Tyr148, Pro103-Thr109, Val149-Asp152, His35, His48, His144, His259, Asp24, Lys37, Lys58, Asp100, Ile107, Glu111, Met113, Asp127, Asp128, Gly130, Gly134, Lys147, Gln150, Asp152, Phe153, Lys154, Val169, Asn173, Arg200, Asn214 and Leu219.
Patent NZ-598472-A (NZ)
Title: Flow meter assembly, gate assemblies and methods of flow measurement
Inventor: AUGHTON DAVID JOHN
IPC: G12B9/00
Filed: 2010-08-18
Abstract: A lift gate assembly 500 includes a gate member 501 associated with a frame 502, and which can be raised and/or lowered from between respective closed and open configurations. The frame 502 is associated with and upstream of an apparatus for the measuring transit times of fluid. The apparatus is in the form of a conduit 600 having one or more opposed pairs of acoustic transducers 46 associated with it. The one or more pairs of opposed acoustic transducers 46 are diagonally directed towards each other.
Patent NZ-599969-A (NZ)
Title: An odor seal valve for a waste pipe using a resiliant spring to close the flap of the valve
Inventor: KIRK LYN
IPC: E03C1/28
Filed: 2010-10-22
Abstract: 599969 A valve assembly (10) for use in a drain or waste pipe (12) is disclosed. The valve assembly includes a tubular body (25) having a longitudinal passage and an outer surface to be located adjacent the internal surface of a floor waste (11). A seal (29) is mounted on the outer surface to engage the internal surface (16) to of the floor waste. A movable valve member (33) is movable between an open position providing for the flow of water from an upstream end to a downstream end of the passage of the tubular body and a closed position closing the passage. Resilient means, such as a spring (34), urges the valve member to the closed position. The resilient means is configured to provide for displacement of the valve member toward the open position when pressure beyond a predetermined pressure is applied upon the movable valve member. When assembling, the floor waste 11 is inserted in the waste pipe by sliding a seal (21) down the inner surface of the waste pipe. The valve assembly is inserted in the floor waste by sliding the seal (29) down the internal surface (16) and then locating a grate (23) on a flange (22) of the floor waste.
Patent NZ-600416-A (NZ)
Title: 2-arylimidazole derivatives as pde10a enzyme inhibitors
Inventor: LANGGARD MORTEN
IPC: A61K31/4178
Filed: 2010-12-15
Abstract: 600416 Disclosed are 4-bicycloheteroarylalkyl-2-phenyl-imidazole derivatives as represented by the general formula (I), wherein: HET-1 is a heteroaromatic group of formula II containing from 2 to 4 nitrogen atoms, and which is preferably selected from [1,2,4]triazolo[1,5-a]pyrazine or [1,2,4]triazolo[1,5-a]pyridine, and which may be optionally substituted; Q is phenyl, optionally substituted with one to five substituents, or a monocyclic 5-membered or 6-membered heteroaromatic group containing 1 or 2 heteroatoms; L is a linker selected from S-CH2, CH2-S, ethylene, ethenylene or ethynylene; R1 is selected from H, alkyl, alkylcycloalkyl, hydroxyalkyl, CH2CN, CH2C(O)NH2, arylalkyl or alkylheterocycloalkyl; and tautomers, pharmaceutically acceptable salts and polymorphic forms thereof, provided that the compound is not 2-(5-phenyl-1H-imidazol-2-ylmethylsulfanyl)-1H-benzoimidazole or 2-(5-phenyl-1H-imidazol-2-yl-sulfanyl-methyl)-1H-benzoimidazole. Important compounds include 5,8-dimethyl-2-[2-(2-phenyl-1H-imidazol-4-yl)-ethyl][1,2,4]triazolo[1,5-a]pyrazine, 5,8-dimethyl-2-[2-(1-methyl-2-phenyl-1H-imidazol-4-yl)-ethyl]-[1,2,4]triazolo[1,5-a]pyrazine and 8-ethyl-5-methyl-2-[2-(1-methyl-2-phenyl-1H-imidazol-4-yl)-ethyl]-[1,2,4]triazolo[1,5-a]pyridine. Also disclosed is a pharmaceutical composition comprising a therapeutically effective amount of a compound as defined above, and one or more pharmaceutically acceptable carriers, diluents and excipients, for the treatment of a neurodegenerative or psychiatric disorder, alone or in combination with one or more neuroleptic agents such as sertindole, olanzapine, risperidone, quetiapine, aripiprazole, haloperidol, c1ozapine, ziprasidone and osanetant, including disorders such as Alzheimer's disease, multi-infarct dementia, alcoholic dementia or other drug-related dementia, dementia associated with intracranial tumors or cerebral trauma, dementia associated with Huntington's disease or Parkinson's disease, or AIDS-related dementia, delirium, amnestic disorder, post-traumatic stress disorder, mental retardation, learning disorders, attention-deficit/hyperactivity disorder, age-related cognitive decline, schizophrenia etc. etc..
Patent NZ-601064-A (NZ)
Title: Clearing redundant data in wireless mesh network
Inventor: MASON ROBERT T
IPC: H04H20/71
Filed: 2011-01-28
Abstract: Disclosed is a wireless network (600) including a control node (602) configured to effect the clearing of message queues of a plurality of communication nodes (604a-604g) in wireless communication with the control node (602). Each of the communication nodes (604a-604g) has a wireless communication path to the control node (602) that is either a direct path or an indirect path through one or more other communication nodes (604a-604g) that serve as repeaters. The control node (602) is configured to broadcast a clear broadcast message to the plurality of communication nodes (604a-604g) after receiving a specified quantity of two or more broadcast messages associated with different respective broadcast message identifiers. The clear broadcast message includes each of the different respective broadcast message identifiers and causes the plurality of communication nodes (604a-604g) to clear messages having any of the different respective broadcast message identifiers from their respective message queues. The control node (602) delays broadcasting of the clear broadcast message at least until receiving the specified quantity of two or more broadcast messages each associated with a different respective broadcast message identifier.
Patent NZ-611581-A (NZ)
Title: Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer
Inventor: DEBUSSCHE LAURENT
IPC: A61P35/00
Filed: 2011-12-08
Abstract: Disclosed is a composition comprising a MEK inhibitor compound of formula (I) (also known as MSC1936369 or AS703026 or MSC6369) and a PI3K inhibitor compound of either formula (2a) (also known as XL147 or SAR245408) or formula (2b) (also known as XL765, SAR245409 or MSC0765). The compositions are useful in the treatment of cancer and reducing tumour size.
Patent NZ-611938-A (NZ)
Title: A support unit for use in a mattress or cushion
Inventor: PAUL LONGMAN
IPC: A47C27/00
Filed: 2013-06-13
Abstract: A support unit (100) for use in a mattress or cushion is disclosed. The support unit comprises an array of upright primary coil springs (110) arranged in a series of aligned rows (111) and columns (112) so as to define voids (117) between sets of four adjacent primary coil springs (110). Secondary support elements (120) are located in at least several of the voids (117). Then elements could be springs or foam columns. The support unit may be divided into zones characterised by different density or patterning’s of the secondary support elements. The lower ends of the primary coil springs and secondary support elements all lie substantially in a common plane, such that the upper ends of the secondary support elements lie in a plane below the plane of the upper ends of the primary coil springs. This results in the secondary support elements having no support effect until a load sufficient to compress the primary coil spring by an amount equal to the difference in heights between the primary coil springs and the secondary support elements is achieved. The additional support provided by the secondary support elements is thus only effectively achieved when the support unit is subjected to a heavy local load, either as a result of a heavier body mass of the person lying on the mattress or localised increased load resulting, for example, from a person sitting or standing in a localised area of the support unit.
Patent NZ-617063-A (NZ)
Title: Systems, methods and apparatuses for creating, editing, distributing and viewing electronic greeting cards
Inventor: ANGORN MATTHEW DAVID
IPC: H04W4/12
Filed: 2012-04-30
Abstract: An electronic greeting card system including an application downloadable to a portable computing device comprises a server; a paper greeting card; a code printed on the paper greeting card; an electronic greeting card application program that is downloaded to the portable computing device from the server in response to the portable computing device scanning the code on the paper greeting card; a category of greeting cards provided by the electronic greeting card application; a greeting card within the category of greeting cards and a means for selecting a medium to be used to send the greeting card from a group of sending media provided by the electronic greeting card application. The greeting card comprises four pages, with at least one of the four pages having an option to customize, and each of the four pages being movable by a touch of a finger. An electronic greeting card application for a portable computing device, comprises a category of greeting cards; at least one greeting card within the category of greeting cards, wherein the at least one greeting card comprises four pages, with at least one of the four pages having an option to customize, and each of the four pages being movable by a touch of a finger; a means for previewing the greeting card; and a means for selecting a medium to be used to send the greeting card.
Patent NZ-622145-A (NZ)
Title: High concentration antibody formulations
Inventor: Zhou xiao-hong
IPC: C07K1/02
Filed: 2012-03-07
Abstract: Disclosed is a method for producing a concentrated antibody solution comprising greater than 100 mg/mL of an anti-C5 antibody, the method comprising: providing a first aqueous solution comprising an anti-C5 antibody, the first aqueous solution having a first formulation and comprising no more than 50 mg/mL of the anti-C5 antibody; subjecting the first aqueous solution to diafiltration to thereby produce a second aqueous solution, wherein the second aqueous solution has a second formulation as a result of the diafiltration; and concentrating the second aqueous solution to produce a concentrated antibody solution comprising greater than 100 mg/mL of the anti-C5 antibody.
Patent NZ-704975-A (NZ)
Title: Retaining system
Inventor: WILSON MALCOLM
IPC: E04H17/20
Filed: 2013-08-01
Abstract: Embodiments of the invention relate to the retention of fence mesh, fence wires and flexible screens to stakes, pickets and the like and which avoid the need for individual ties. In particular, in some embodiments the retention effect is provided by a slotted tube engaged around the stake or picket to provide retention over the full height of the stake or picket. In other embodiments the stake or picket is slotted to receive fence wires or the wires of fence mesh with locking means applied to the picket or stake to retain the wires in the slots.
Patent NZ-706048-A (NZ)
Title: Animal handling apparatus
Inventor: HILL PETER
IPC: A61D3/00
Filed: 2013-08-21
Abstract: An apparatus for supporting sheep during shearing is disclosed. The apparatus includes lifting and rotating means, and is able to move between a first position in which it can be used to acquire a sheep and a second position suitable for holding the sheep during shearing. In the second position the rotating means allows for a sheep to be rotated about a vertical axis during shearing.
Patent NZ-706471-A (NZ)
Title: Blower and pap system
Inventor: MOIR MICHAEL BRUCE
IPC: F04D29/66
Filed: 2012-02-22
Abstract: A positive airway pressure (PAP) device adapted to supply pressurised, breathable gas for treatment for respiratory diseases or sleep-disordered breathing like sleep apnoea. The PAP device comprises a housing, an inlet elbow (142) and a blower (105). The housing comprises an upper housing (101) and a lower housing sealed together. The upper housing includes an air inlet (131) which may be adapted to house a filter (140). The inlet elbow (142) is in fluid communication with the air inlet and is adapted to direct air flow from the air inlet to the lower housing. The inlet elbow may be curved to reflect sound waves and may disperse air in 360 degrees to an internal area formed within the housing. The inlet elbow may be formed of a flexible elastomeric material for example silicone. The blower (142) comprises a blower housing comprising an inlet (127) and an outlet (151). The blower (142) comprises an impeller and a motor within the housing. The motor comprises a shaft adapted to drive the impeller. A stationary component is provided in the housing and may support the motor. The impeller is positioned between the inlet of the blower housing and the stationary component.
Patent NZ-721900-A (NZ)
Title: Proliposomal testosterone formulations
Inventor: BETAGERI GURU V
IPC: A61P5/26
Filed: 2013-05-09
Abstract: Novel testosterone formulations are disclosed where testosterone is incorporated into a phospholipid/ cholesterol system to produce a proliposomal powder dispersion. The proliposomal powder dispersions of the invention may be formulated with phamarceutically acceptable excipients to form pharmaceutical compositions. Enterically coated oral dosage forms are disclosed as are methods of treatment for testosterone replacement therapy.